Literature DB >> 23588235

A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome.

B Le Nevé1, I Posserud, L Böhn, D Guyonnet, P Rondeau, K Tillisch, B Naliboff, E A Mayer, M Simrén.   

Abstract

OBJECTIVES: The aim of the present pilot study was to evaluate the usefulness of a test meal containing lactulose in the non-invasive assessment of visceral sensitivity in irritable bowel syndrome (IBS), and to identify subsets of IBS patients based on gastrointestinal (GI) symptom generation.
METHODS: We included 43 patients with IBS (Rome III) and 29 healthy controls. The fasted subjects were served three test meals consisting of a 400-ml liquid breakfast alone or containing lactulose (15 or 25 g) in a double-blind crossover design. Seven GI symptoms, overall digestive comfort, and exhaled H2/CH4 were assessed at baseline and every 15 min during 4 h after meal intake. Anxiety and depression were assessed only at baseline. A mapping of the seven GI symptoms was done using a Principal Component Analysis (4 h mean area under the curve, AUC). Independently, a hierarchical cluster analysis was performed on the same parameters to identify GI symptom-based IBS clusters.
RESULTS: All three tests were well tolerated. The 25 g lactulose challenge enabled discrimination of IBS from healthy controls according to the symptom response. This challenge also enabled clustering of IBS subjects in two subgroups based mainly on bloating, distension, and discomfort symptoms (2,457 (2,043-2,872), 2,450 (1,910-2,990), 2,602 (2,126-3,079) vs. 537 (383-691), 619 (458-780), 643 (432-854); 4 h mean AUC; P<0.0001), overall digestive comfort (1807 (1318-2295) vs. 3350 (2942-3758); 4 h mean AUC; P<0.0001), and anxiety at baseline (9.2 (7.0-11.5) vs. 5.5 (4.2-6.9); Hospital Anxiety and Depression scale anxiety mean scores; P=0.003). This clustering was independent of the Rome III subtype and the amount of exhaled H2/CH4.
CONCLUSIONS: The lactulose challenge test seems to be a promising tool to assess visceral sensitivity in IBS, and to subgroup IBS patients based on their symptom pattern.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588235     DOI: 10.1038/ajg.2013.75

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 2.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

3.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

Review 4.  Breath tests and irritable bowel syndrome.

Authors:  Satya Vati Rana; Aastha Malik
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

5.  Systemic symptoms in irritable bowel syndrome: An investigative study on the role of enterocyte disintegrity, endotoxemia and inflammation.

Authors:  Ragnhild Undseth; Arnold Berstad; Jørgen Valeur
Journal:  Mol Med Rep       Date:  2016-10-21       Impact factor: 2.952

6.  Fasting breath H2 and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome.

Authors:  Boris Le Nevé; Muriel Derrien; Julien Tap; Rémi Brazeilles; Stéphanie Cools Portier; Denis Guyonnet; Lena Ohman; Stine Störsrud; Hans Törnblom; Magnus Simrén
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

7.  Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis.

Authors:  Jennifer S Labus; Vadim Osadchiy; Elaine Y Hsiao; Julien Tap; Muriel Derrien; Arpana Gupta; Kirsten Tillisch; Boris Le Nevé; Cecilia Grinsvall; Maria Ljungberg; Lena Öhman; Hans Törnblom; Magnus Simren; Emeran A Mayer
Journal:  Microbiome       Date:  2019-03-21       Impact factor: 14.650

8.  Efficacy and safety of lactulose for the treatment of irritable bowel syndrome.

Authors:  Hong-Bin Chen; Xiao-Ying Su
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

Review 9.  European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus.

Authors:  Heinz F Hammer; Mark R Fox; Jutta Keller; Silvia Salvatore; Guido Basilisco; Johann Hammer; Loris Lopetuso; Marc Benninga; Osvaldo Borrelli; Dan Dumitrascu; Bruno Hauser; Laszlo Herszenyi; Radislav Nakov; Daniel Pohl; Nikhil Thapar; Marc Sonyi
Journal:  United European Gastroenterol J       Date:  2021-08-25       Impact factor: 4.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.